A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.
van der Lee, SJ
Al Olama, AA
den Hoed, M
van der A, DL
van der Schouw, YT
MetadataShow full item record
Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic therapies by predicting cardiovascular and other health endpoints. We therefore investigated the association of variants in six genes that encode drug targets for obesity or T2D with a range of metabolic traits in up to 11,806 individuals by targeted exome sequencing and follow-up in 39,979 individuals by targeted genotyping, with additional in silico follow-up in consortia. We used these data to first compare associations of variants in genes encoding drug targets with the effects of pharmacological manipulation of those targets in clinical trials. We then tested the association of those variants with disease outcomes, including coronary heart disease, to predict cardiovascular safety of these agents. A low-frequency missense variant (Ala316Thr; rs10305492) in the gene encoding glucagon-like peptide-1 receptor (GLP1R), the target of GLP1R agonists, was associated with lower fasting glucose and T2D risk, consistent with GLP1R agonist therapies. The minor allele was also associated with protection against heart disease, thus providing evidence that GLP1R agonists are not likely to be associated with an unacceptable increase in cardiovascular risk. Our results provide an encouraging signal that these agents may be associated with benefit, a question currently being addressed in randomized controlled trials. Genetic variants associated with metabolic traits and multiple disease outcomes can be used to validate therapeutic targets at an early stage in the drug development process.
Version of record
Neurology Working Group of the Cohorts for Heart
Aging Research in Genomic Epidemiology (CHARGE)
Alzheimer’s Disease Genetics Consortium
Pancreatic Cancer Cohort Consortium
European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD)
CHD Exome+ Consortium
CARDIOGRAM Exome Consortium
License start date
Science translational medicine, 2016, 8 (341), pp. 341ra76 - ?
Showing items related by title, author, creator and subject.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Arce Vargas, F; Furness, AJS; Solomon, I; Joshi, K; Mekkaoui, L; Lesko, MH; Miranda Rota, E; Dahan, R; Georgiou, A; Sledzinska, A; Ben Aissa, A; Franz, D; Werner Sunderland, M; Wong, YNS; Henry, JY; O'Brien, T; Nicol, D; Challacombe, B; Beers, SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium; Turajlic, S; Gore, M; Larkin, J; Swanton, C; Chester, KA; Pule, M; Ravetch, JV; Marafioti, T; Peggs, KS; Quezada, SACD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We ...
The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. Kerkmeijer, LGW; Fuller, CD; Verkooijen, HM; Verheij, M; Choudhury, A; Harrington, KJ; Schultz, C; Sahgal, A; Frank, SJ; Goldwein, J; Brown, KJ; Minsky, BD; van Vulpen, M; MR-Linac Consortium Clinical Steering Committee (2016)An international research consortium has been formed to facilitate evidence-based introduction of MR-guided radiotherapy (MR-linac) and to address how the MR-linac could be used to achieve an optimized radiation treatment ...
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. Luedeke, M; Rinckleb, AE; FitzGerald, LM; Geybels, MS; Schleutker, J; Eeles, RA; Teixeira, MR; Cannon-Albright, L; Ostrander, EA; Weikert, S; Herkommer, K; Wahlfors, T; Visakorpi, T; Leinonen, KA; Tammela, TLJ; Cooper, CS; Kote-Jarai, Z; Edwards, S; Goh, CL; McCarthy, F; Parker, C; Flohr, P; Paulo, P; Jerónimo, C; Henrique, R; Krause, H; Wach, S; Lieb, V; Rau, TT; Vogel, W; Kuefer, R; Hofer, MD; Perner, S; Rubin, MA; Agarwal, AM; Easton, DF; Al Olama, AA; Benlloch, S; PRACTICAL consortium; Hoegel, J; Stanford, JL; Maier, CMolecular and epidemiological differences have been described between TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer (PrCa). Assuming two molecularly distinct subtypes, we have examined 27 common PrCa risk ...